GlaxoSmithKline is unconcerned about losing its position in the respiratory market as Mylan launches the first generic version of blockbuster asthma product Seretide in the UK.
There is still demand for alternative to injection for insulin despite the subdued launch of Sanofi’s Afrezza, Oramed says as it pushes forward with its oral candidate.
Dutch scientists have 3D printed a protective scaffold that could make cell transplant-based diabetes treatment more successful and eliminate the need for immunosupressive drugs.
Novartis has partnered with Google-backed Rani Therapeutics to assess an oral platform which delivers biologics through the intestinal wall using needles made of sugar.
Sanofi's inhaled insulin drug Affrezza has generated lower than expected revenue due to marketing delays rather than low demand according to MannKind CFO, Matthew Pfeffer.
Vaccines being developed using Catalent's oral Zydis platform would increase compliance and cut costs but Big Pharma is slow to get on board, the firm says.
Capsugel says it is bolstering its service to offer specialised dry powder inhalation (DPI) formulations, allowing biotherapeutics to be delivered to the lung rather than by injection.
A liquid-gel which solidifies in the stomach could offer drugmakers an effective modified-release delivery option, according to the lead scientist behind the project.
BASF, Abitec and Gattefossé dominate the solubility excipients market but growing demand for tech to enhance API solubility is creating opportunities for smaller suppliers according to new research.
Recipharm has invested $2m (EUR1.8m) in metal co-ordinated chemistry (MCC) specialist Synthonics in a deal that will also see it help develop the US firm’s range of targeted drug products.
A drug candidate which prevents the export of viral RNA in infected cells could lead the way in developing a functional cure for HIV, according to Abivax.
The European Investment Bank (EIB) has loaned Innocoll AG €25m to support development of a post-surgical painkiller and diabetes-related infection drug delivered using its collagen-based tech.
More cancer drugs are going to be delivered using nanoparticles according to Frost & Sullivan, which says research breakthroughs are going to drive adoption of such technologies.
A type 1 diabetes vaccine will enter human trials this year according to the leader of the UK research team developing a preventative therapy for the autoimmune disorder.
Cancer Drug firms trying to block protein kinase Cs should rethink say researchers behind a study indicating that the enzymes suppress tumour development.
US desire for an alternative to the current multi-shot anthrax vaccine is a boon for delivery systems firm Glide Technologies, which had its contract extended by Pfenex this week.
‘Smart’ syringes that can’t be reused should be the drug and vaccine delivery technology of choice for healthcare programmes according to the WHO, which says needle reuse is spreading deadly infectious diseases.
A potential Type 2 diabetes drug from Novo Nordisk has met the primary endpoint of a Phase II trial and shares of Emisphere Technology, which helped to formulate the oral version of semaglutide, jumped by as much as 70% on Friday.
Lupin will co-develop a rival to GSK’s Advair in the US and has licensed rights to an inhaled drug delivery tech competitor for Forest Labs’s Aerochamber.
Having shorter hair stops you becoming fat…at least it does if you are a stem cell say researchers who claim restricting the growth of hair-like cilia found on such cells could yield new treatments for obesity.
Opioid addiction drug Suboxone lost market share in 2014 according to newly independent Indivior, whose management says it is not intimidated by increased competition.
Researchers from the Oncology Department of Tianjin Medical University Cancer Hospital in China recently published a study in Advanced Functional Materials announcing the creation of a new nano-carrier for pancreatic cancer treatments.
Pfizer, Lilly and Novo Nordisk will not be revisiting inhaled insulin opportunities despite the US launch and expected success of Sanofi and MannKind’s Afrezza.
Big Pharma firms like AbbVie are partnering with delivery device makers to guard against biosimilar competition according to Unilife CEO, Alan Shortall.
